RNTX 10-Q: SEC filing

Rein Therapeutics

Filed with the SEC on · accession 0001193125-26-461944

RNTX filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Rein Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing various financing arrangements, including pre-paid advance agreements with YA II PN Ltd and warrant issuances.

Key details

Financing counterparty under pre-paid advance agreementsYA II PN Ltd
Underwriter for warrant offeringsKonik Capital
Sales agent for at-the-market offeringWainwright

✦ Ask GOAX AI about this filing — what it means for RNTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RNTX?

Click here

Frequently asked questions

What did RNTX file with the SEC on Nov 16, 2026?

RNTX filed a 10-Q (SEC filing). Rein Therapeutics filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing various financing arrangements, including pre-paid advance agreements with YA II PN Ltd and warrant issuances.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other RNTX SEC filings

Get alerts when RNTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days